Two Onc Docs

We are updating another important GYN ONC topic: endometrial (uterine) cancer. We will go over all the important details on the risk factors, presentation, diagnosis, staging & treatment options. We will also cover rare uterine malignancies at the end of the episode.

Today’s episode we will cover 2025 updates for metastatic renal cell carcinoma. We will discuss risk categories, treatment options, and variant histologies. We are so excited to have Dr. Tom Powles and Dr. Brian Rini from the urologic oncology podcast Uromigos sharing their expertise on today's episode as well!

Today’s episode we will cover 2025 updates for localized renal cell carcinoma (RCC) with Dr. Tom Powles and Dr. Brian Rini from the urologic oncology podcast Uromigos! We will discuss risk factors, the presentation, staging, and treatment options. 

This week’s episode will be focusing on Cervical Cancer with some updates since we last released this topic in 2022. We will go over important details on prevention, risk factors, diagnosis & treatment.

This week’s episode is an update on a must-know topics both for new fellows & residents. We will go over clinically important oncologic emergencies including brain metastases, hypercalcemia of malignancy, cord compression and SVC syndrome. 

This week’s episode will be focusing on one of the GI plenary session abstracts presented at the ASCO Annual Meeting 2025,  the MATTERHORN trial: phase 3 durvalumab + FLOT which is 5FU leucovorin, oxaliplatin and docetaxel in resectable gastric or GE junction CA. 

This week’s episode will be focusing on how to prepare for the start of heme/onc fellowship! 

We will go over some general advice on how to succeed, study tips and resources we used throughout fellowship as well as some tips on how to stay academically productive during training if you are planning for an academic career.

This week’s episode will be focusing on one of the 2025 plenary sessions: SERENA-6, Camizestrant, a novel selective estrogen receptor degrader (SERD) + CDK 4/6i for tx of emergent ESR1 during 1L endocrine-based therapy + ahead of progression in stage 4 HR+/Her-2 negative breast cancer.

We discuss the trial design, endpoints, results, safety concerns, and how it fits into current practice.

This week’s episode will be focusing on Ovarian Cancer with 2025 updates since we last covered this topic in 2022. We will go over all important details on the risk factors, presentation, diagnosis, staging & treatment options for both localized and metastatic disease. 

This week’s episode will be focusing on exciting data in GU presented at the 2025 ASCO Annual Meeting in prostate (including prognostication of PSA response in mCSPC, AMPLITUDE - PARPi in mCSPC), RCC (including updates in KN-564, CM-214 and PDIGREE), and finally bladder CA (with updates in NIAGARA and EV-302) among others.